| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 27.004 | 49.096 | 47.534 | 41.062 | 42.569 | 48.729 | 48.955 |
| Total Income - EUR | - | - | - | 27.004 | 49.096 | 47.534 | 41.062 | 42.569 | 48.729 | 48.955 |
| Total Expenses - EUR | - | - | - | 31.616 | 47.340 | 48.788 | 40.280 | 42.511 | 47.894 | 47.264 |
| Gross Profit/Loss - EUR | - | - | - | -4.612 | 1.756 | -1.254 | 782 | 58 | 835 | 1.690 |
| Net Profit/Loss - EUR | - | - | - | -4.612 | 1.756 | -1.254 | 700 | 58 | 702 | 1.382 |
| Employees | - | - | - | 5 | 5 | 4 | 5 | 5 | 5 | 5 |
Check the financial reports for the company - Primapemed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 28 | 1.256 | 373 | 132 | 1.556 | 2.174 | 4.091 |
| Inventories | - | - | - | 0 | 664 | 58 | 82 | 0 | 0 | 402 |
| Receivables | - | - | - | 0 | 1 | 1 | 1 | 83 | 0 | 0 |
| Cash | - | - | - | 28 | 591 | 315 | 49 | 1.473 | 2.174 | 3.689 |
| Shareholders Funds | - | - | - | -4.569 | -2.724 | -3.269 | -2.494 | -2.443 | -1.734 | -342 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 4.597 | 3.980 | 3.643 | 2.626 | 3.999 | 3.908 | 4.433 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3600 - 3600" | |||||||||
| CAEN Financial Year |
3600
|
|||||||||
Comments - Primapemed S.r.l.